

CITATION REPORT

List of articles citing

Fate of the synthetic immunoadjuvant, muramyl dipeptide (^{14}C -labelled) in the mouse

DOI: 10.1016/0192-0561(79)90028-6

International Journal of Immunopharmacology, 1979, 1, 35-41.

Source: <https://exaly.com/paper-pdf/14094007/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
169	Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. 1979 , 76, 6557-61		62
168	Stimulation of thymocyte mitogenic protein secretion and of cytostatic activity of mouse peritoneal macrophages by trehalose dimycolate and muramyl dipeptide. 1980 , 10, 647-53		63
167	Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide. 1980 , 142, 708-15		69
166	In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. 1981 , 57, 42-50		121
165	Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. 1981 , 78, 1680-4		271
164	Muramyl peptides. Chemical structure, biological activity and mechanism of action. 1981 , 41, 27-47		106
163	Control of the mitogenicity of muramyl dipeptide. <i>International Journal of Immunopharmacology</i> , 1981 , 3, 31-44		19
162	Analysis of the antigenic relationship of various derivatives of n-acetyl-muramyl-l-ala-d-isoglutamine (MDP), using anti-MDP antibodies. 1982 , 19, 737-45		7
161	Fate of two ¹⁴ C labelled muramyl peptides: Ac-Mur-L-Ala-gamma-D-Glu-meso-A2pm and Ac-Mur-L-Ala-gamma-D-Glu-meso-A2pm-D-Ala-D-Ala in mice. Evaluation of their ability to increase non specific resistance to Klebsiella infection. <i>International Journal of Immunopharmacology</i> , 1982 , 4, 143-9		22
160	Effect of immunomodulating agents on leucocyte chemotaxis and cyclic nucleotides. 1982 , 12, 353-9		14
159	Sex hormonal effects on the severity of streptococcal cell wall-induced polyarthritis in the rat. 1983 , 26, 560-3		74
158	The pathogenesis of group A streptococcal cell wall-induced polyarthritis in the rat. Comparative studies in arthritis resistant and susceptible inbred rat strains. 1983 , 26, 1442-51		76
157	The synthesis of N-[³ H] acetyl muramyl dipeptides of high specific radioactivity. 1983 , 20, 691-696		4
156	Effects of treatment with muramyl dipeptide on resistance to Mycobacterium leprae and Mycobacterium marinum infection in mice. 1983 , 5, 329-39		7
155	Bayliss-Starling Memorial Lecture (1982). Induction of sleep by muramyl peptides. 1983 , 336, 1-11		16
154	Muramyl peptides as possible endogenous immunopharmacological mediators. 1983 , 27, 723-32		38
153	Systemic Activation of Macrophages and Treatment of Cancer Metastases by Liposomes containing Hydrophilic or Lipophilic Muramyl Dipeptide. 1983 , 235-241		13

152	Inhibition of endogenous pyrogen-induced fever by a muramyl dipeptide derivative. 1984 , 247, C169-74	11
151	Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. 1984 , 224, 1007-9	69
150	The fate of nor-muramyl dipeptide (3H-labelled) after local administration in incomplete Freund's adjuvant in the guinea pig. <i>International Journal of Immunopharmacology</i> , 1984 , 6, 119-24	1
149	Modulation of the growth of murine thymoma cell lines having different Lyt-phenotypes by MDP and MDP(D-D): macrophage-mediated inhibition of in vitro cell growth. <i>International Journal of Immunopharmacology</i> , 1984 , 6, 577-85	7
148	Pharmacokinetics and metabolism of muramyl dipeptide and nor-muramyl dipeptide [3H-labelled] in the mouse. <i>International Journal of Immunopharmacology</i> , 1984 , 6, 133-9	31
147	Selective macrophage activation by muramyl dipeptide bound to monoclonal antibodies specific for mouse tumor cells. 1984 , 18, 155-9	13
146	<i>Leishmania tropica</i> : protective response in C3H mice vaccinated with excreted factor crosslinked with the synthetic adjuvant, muramyl dipeptide. 1984 , 58, 223-9	14
145	Liposome mediated delivery of biological response modifiers (BRM) to macrophages in vivo: A new strategy for therapy of neoplastic disease. 1985 , 14, 339-348	
144	Liposome mediated delivery of biological response modifiers (BRM) to macrophages in vivo: A new strategy for therapy of neoplastic disease. 1985 , 14, 339-348	
143	The systemic activation of macrophages by liposomes containing immunomodulators. 1985 , 8, 413-28	7
142	Reactivation of streptococcal cell wall-induced arthritis by homologous and heterologous cell wall polymers. 1985 , 28, 1402-11	59
141	Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide. 1985 , 228, 495-7	62
140	Design of sterile muramyl dipeptide-containing oligolamellar liposomes suitable for i.v. injection. Effect of liposome size and lipid composition on their ability to render peritoneal macrophages antitumoral. 1985 , 23, 299-313	6
139	Preparation and characterisation of liposomes containing mannosylated phospholipids capable of targeting drugs to macrophages. 1986 , 862, 153-64	63
138	Peptides and related drugs: a review of their absorption, metabolism, and excretion. 1986 , 17, 283-310	139
137	Liposome encapsulation of muramyl peptides for activation of macrophage cytotoxic properties. 1986 , 132, 594-603	2
136	Modulation of pulmonary macrophage superoxide release and tumoricidal activity following activation by biological response modifiers. 1986 , 12, 117-26	13
135	Activation of macrophage in vitro to acquire antitumor activity by a muramyl dipeptide derivative encapsulated in microspheres composed of lactide copolymer. 1987 , 6, 189-204	9

134	Drug delivery to macrophages for the therapy of cancer and infectious diseases. 1987 , 507, 141-54	19
133	The biology of cancer metastasis and implications for therapy. 1987 , 24, 129-209	137
132	Use of mannosylated liposomes for in vivo targeting of a macrophage activator and control of artificial pulmonary metastases. 1987 , 138, 437-50	29
131	Relationship of metabolism and immunostimulating activity of peptidoglycan monomer in mice after three different routes of administration. <i>International Journal of Immunopharmacology</i> , 1987 , 9, 325-32	8
130	Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes. <i>International Journal of Immunopharmacology</i> , 1987 , 9, 141-50	24
129	Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide. 1988 , 8, 1046-50	36
128	Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. 1988 , 2, 69-106	46
127	Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. 1988 , 948, 151-73	72
126	Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide. 1988 , 85, 6112-6	16
125	Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers. 1989 , 29, 685-94	57
124	Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators. 1989 , 6, 241-55	57
123	Muramylpeptides and lipopeptides: Studies towards immunostimulants. 1989 , 45, 6331-6360	76
122	Kupffer cells and liver metastasis. Optimization and limitation of activation of tumoricidal activity. 1989 , 8, 231-52	58
121	Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide. 1989 , 28, 54-8	27
120	Role of bacterial debris in inflammatory diseases of the joint and eye. 1990 , 98, 957-68	25
119	Syntheses of polymeric vesicles containing partial structures of N-acetyl-muramyl-dipeptide (MDP). 1990 , 53, 347-56	
118	Synthesis of muramoyl tripeptides and their isotope-labeled analogues. 1990 , 26, 199-201	
117	Macrophages and cancer. 1990 , 8, 319-51	82

116	Uptake of muramyl dipeptide fluorescent congeners by normal rabbit bronchoalveolar lavage cells: a study using flow cytometry. 1990 , 2, 171-81	4
115	Therapy of murine liver metastases by administration of MDP encapsulated in liposomes. 1990 , 6, 63-71	20
114	Modulation of the blood-aqueous barrier by gram positive and gram negative bacterial cell wall components in the rat and rabbit. 1990 , 50, 189-95	20
113	Anti-metastatic activity in vivo of MDP-L-alanyl-cholesterol (MTP-Chol) entrapped in nanocapsules. <i>International Journal of Immunopharmacology</i> , 1991 , 13, 167-73	9
112	In vivo modulation of atypical mycobacterial infection: adjuvant therapy increases resistance to <i>Mycobacterium avium</i> by enhancing macrophage effector functions. 1991 , 134, 42-53	5
111	Enhancing effect of cetylmannoside on targeting of liposomes to Kupffer cells in rats. 1991 , 70, 225-233	17
110	<i>Leishmania donovani</i> in hamsters: stimulation of non-specific resistance by some novel glycopeptides and impact on therapeutic efficacy. 1991 , 47, 486-90	17
109	Liposomal delivery of biological response modifiers to macrophages. 1991 , 3, 55-64	14
108	Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. 1991 , 13, 101-19	10
107	Differences in proinflammatory activity of several immunomodulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects. 1992 , 36, 136-45	12
106	Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE. 1993 , 82, 997-1001	17
105	T-cell-dependent immunobiological activity of a desmuramyl analog of muramyl dipeptide, adamantylamide dipeptide (AdDP), and D-isoglutamine. <i>International Journal of Immunopharmacology</i> , 1993 , 15, 631-7	4
104	Pharmacokinetics of an immunomodulator peptidoglycan monomer in mice after intravenous administration. <i>International Journal of Immunopharmacology</i> , 1993 , 15, 145-50	2
103	Targeting of muramyl dipeptide to macrophages by gelatin conjugation to enhance their in vivo antitumor activity. 1993 , 27, 79-88	13
102	Some cellular and pathophysiological correlates of the inflammatory effects of a synthetic immunomodulatory agent, muramyl dipeptide (MDP). 1993 , 38, 106-15	5
101	Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide. 1993 , 7, 1-12	14
100	Immunization against <i>Echis ocellatus</i> (carpet viper) venom using liposomes incorporating immunostimulants: role of lipopolysaccharide in conferring protection in a mouse model. 1993 , 31, 615-26	10
99	Adjuvants--a balance between toxicity and adjuvanticity. 1993 , 11, 293-306	379

98	Modification of reticuloendothelial function by muramyl dipeptide-encapsulated liposomes in jaundiced rats treated with biliary decompression. 1993 , 28, 53-62	4
97	Liposomal Applications to Cancer Therapy. 1993 , 8, 158-177	11
96	Biodegradable nanocapsules containing a lipophilic immunomodulator: drug retention and tolerance towards macrophages in vitro. 1993 , 1, 157-64	12
95	Therapy of cancer metastasis by systemic activation of macrophages. 1994 , 30, 271-326	29
94	Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats. 1994 , 9, 329-40	7
93	Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules. <i>International Journal of Immunopharmacology</i> , 1994 , 16, 451-6	12
92	Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules. <i>International Journal of Immunopharmacology</i> , 1994 , 16, 457-61	23
91	Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis. 1994 , 13, 325-340	8
90	Synthesis of phthalimido-desmuramylpeptide analogues as potential immunomodulating agents. 1995 , 328, 113-7	14
89	<i>Leishmania donovani</i> in hamsters: stimulation of non-specific resistance by novel lipopeptides and their effect in antileishmanial therapy. 1995 , 51, 725-30	8
88	Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study. 1995 , 10, 125-30	20
87	Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen. 1995 , 13, 77-82	20
86	Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives. <i>Journal of Medicinal Chemistry</i> , 1996 , 39, 4483-8	8.3 18
85	Liposomal phosphatidylserine inhibits tumor cytotoxicity of liver macrophages induced by muramyl dipeptide and lipopolysaccharide. 1996 , 1285, 219-28	9
84	Relationship between NO-synthase activity and TNF-alpha secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules. <i>International Journal of Immunopharmacology</i> , 1996 , 18, 385-92	4
83	Distinctive immunomodulating properties and interactivity with model membranes and cells of two homologous muramyl dipeptide derivatives differing by their lipophilicity. <i>International Journal of Immunopharmacology</i> , 1996 , 18, 651-9	6
82	Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro. 1997 , 15, 1479-86	18
81	Lipophilic drug derivatives in liposomes. 1998 , 165, 129-168	171

80	Protein-loaded poly(epsilon-caprolactone) microparticles. II. Muramyl dipeptide for oral controlled release of adjuvant. 1999 , 16, 601-12		20
79	Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. I. In vitro characterization. 2000 , 69, 53-67		8
78	Failure To detect muramic acid in normal rat tissues but detection in cerebrospinal fluids from patients with Pneumococcal meningitis. <i>Infection and Immunity</i> , 2000 , 68, 4688-98	3.7	22
77	Profiling and Trace Detection of Bacterial Cellular Carbohydrates. 2002 , 341-357		
76	Pharmacokinetics and feeding responses to muramyl dipeptide in rats. 2003 , 79, 173-82		13
75	Site-specific drug delivery using liposomes as carriers*. 2003 ,		
74	Efficacy of human beta-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters. 2004 , 25, 1873-81		20
73	Non-specific stimulation of host defenses against a bacterial challenge in malnourished hosts. 1982 , 69, 665-8		13
72	A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 5112-22	8.3	18
71	Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2. 2008 , 26, 5808-13		33
70	NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. 2008 , 49, 1518-24		35
69	Effect of muramyl peptides on mitochondrial respiration. <i>Clinical and Experimental Immunology</i> , 2009 , 155, 72-8	6.2	3
68	Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines. <i>AAPS Journal</i> , 2009 , 11, 139-47	3.7	25
67	Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 165-77	3	13
66	Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. <i>Journal of Pharmacy and Pharmacology</i> , 1987 , 39, 698-704	4.8	61
65	Macrophage activation for antitumour function by muramyl dipeptide-protein conjugates. <i>Journal of Pharmacy and Pharmacology</i> , 1990 , 42, 13-9	4.8	14
64	Site-Specific Drug Delivery Using Liposomes and Emulsions as Carriers. 2011 , 1-46		
63	New muramyl dipeptide (MDP) mimics without the carbohydrate moiety as potential adjuvant candidates for a therapeutic hepatitis B vaccine (HBV). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 4292-5	2.9	10

62	The biology of bacterial peptidoglycans and their impact on host immunity and physiology. <i>Cellular Microbiology</i> , 2014 , 16, 1014-23	3.9	41
61	Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 804, 307-21	3.6	39
60	Strengthening peptide-based drug activity with novel glyconanoparticle. <i>PLoS ONE</i> , 2018 , 13, e0204472	3.7	5
59	A cell-based test system for the assessment of pharmacokinetics of NOD1 and NOD2 receptor agonists. <i>International Immunopharmacology</i> , 2018 , 63, 94-100	5.8	1
58	Chronic myeloid leukemia stem cells. <i>Leukemia</i> , 2019 , 33, 1543-1556	10.7	70
57	Translation of peptidoglycan metabolites into immunotherapeutics. <i>Clinical and Translational Immunology</i> , 2019 , 8, e1095	6.8	11
56	Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2019 , 39, 1447-1484	14.4	15
55	The Role of the Bacterial Muramyl Dipeptide in the Regulation of GLP-1 and Glycemia. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
54	Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their Adjuvant Activity. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 7809-7838	8.3	2
53	The Recognition and Destruction of Metastatic Cells by Tumoricidal Macrophages. 1986 , 199-212		1
52	The Use of Activated Macrophages for the Destruction of Heterogeneous Metastasis. 1986 , 207-226		2
51	Role of Macrophages in Host Resistance Against Tumors. <i>Cancer Treatment and Research</i> , 1983 , 83-106	3.5	2
50	The Characterization of Immunotherapeutic Agents. 1990 , 1-64		1
49	Pharmacokinetics of Immunomodulators. 1990 , 65-87		1
48	Effects of Microbially Derived Products on Mononuclear Phagocytes. 1985 , 181-245		1
47	Liposome targeting to macrophages: opportunities for treatment of infectious diseases. <i>Advances in Experimental Medicine and Biology</i> , 1986 , 202, 171-84	3.6	10
46	Immunomodulation by BCG and Synthetic Bacterial-Like Adjuvants. 1981 , 151-163		2
45	Macrophages and cancer metastasis. <i>Advances in Experimental Medicine and Biology</i> , 1982 , 155, 65-75	3.6	11

44	Role of Adjuvant and Immunogenic Moieties of <i>M. tuberculosis</i> in Pathogenicity. <i>Infectious Agents and Pathogenesis</i> , 1988 , 39-58		1
43	The Biological Diversity of Malignant Neoplasms. 1982 , 269-299		5
42	Muramyl dipeptides: prospect for cancer treatments and immunostimulation. <i>Advances in Experimental Medicine and Biology</i> , 1983 , 166, 117-58	3.6	22
41	Delivery of Macrophage Activating Factors by Means of Liposomes. 1986 , 285-294		1
40	Eradication of cancer metastasis by tumoricidal macrophages. <i>Advances in Experimental Medicine and Biology</i> , 1988 , 233, 415-23	3.6	5
39	Immunostimulation with peptidoglycan or its synthetic derivatives. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 1988 , 32, 305-28		18
38	Chemistry of Synthetic Immunomodulant Muramyl Peptides. <i>Progress in the Chemistry of Organic Natural Products</i> , 1981 , 1-47	1.9	5
37	Eradication of metastases by tumoricidal macrophages: therapeutic implications. 1982 , 15-27		2
36	Muramyl peptides. 1981 , 27-47		1
35	Natural and Synthetic Immunostimulants and Transmethylase Inhibitors as Antiparasitic Agents in Animal Models. 1981 , 205-222		3
34	Muramyl Peptides as Immunopharmacological Response Modifiers. 1985 , 307-327		8
33	Proinflammatory Microbial Products as Etiologic Agents of Inflammatory Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 1987 , 13, 293-306	2.4	10
32	Protective effect of muramyl dipeptide analogs against infections of <i>Pseudomonas aeruginosa</i> or <i>Candida albicans</i> in mice. <i>Infection and Immunity</i> , 1981 , 34, 676-83	3.7	61
31	Arthritogenic activity of a synthetic immunoadjuvant, muramyl dipeptide. <i>Infection and Immunity</i> , 1982 , 35, 674-9	3.7	27
30	Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections. <i>Infection and Immunity</i> , 1982 , 37, 292-300	3.7	45
29	Protective effect of a muramyl dipeptide analog encapsulated in or mixed with liposomes against <i>Candida albicans</i> infection. <i>Infection and Immunity</i> , 1983 , 39, 172-8	3.7	46
28	Stimulation of chemiluminescence by synthetic muramyl dipeptide and analogs. <i>Infection and Immunity</i> , 1983 , 40, 16-21	3.7	13
27	Qualitative detection of muramic acid in normal mammalian tissues. <i>Infection and Immunity</i> , 1984 , 43, 937-41	3.7	48

26	Two adjuvant-active muramyl dipeptide analogs induce differential production of lymphocyte-activating factor and a factor causing distress in guinea pigs. <i>Infection and Immunity</i> , 1984 , 44, 344-50	3.7	20
25	Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis. <i>Infection and Immunity</i> , 1985 , 48, 409-16	3.7	41
24	Granuloma formation by muramyl dipeptide associated with branched fatty acids, a structure probably essential for tubercle formation by Mycobacterium tuberculosis. <i>Infection and Immunity</i> , 1985 , 49, 244-9	3.7	15
23	Degradation of muramyl dipeptide by mammalian serum. <i>Infection and Immunity</i> , 1985 , 50, 320-1	3.7	21
22	Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice. <i>Infection and Immunity</i> , 1987 , 55, 1426-30	3.7	12
21	Elimination of group A streptococcal cell walls from mammalian tissues. <i>Infection and Immunity</i> , 1987 , 55, 1526-8	3.7	27
20	Rapid elimination of a synthetic adjuvant peptide from the circulation after systemic administration and absence of detectable natural muramyl peptides in normal serum at current analytical limits. <i>Infection and Immunity</i> , 1991 , 59, 1202-5	3.7	27
19	Absolute identification of muramic acid, at trace levels, in human septic synovial fluids in vivo and absence in aseptic fluids. <i>Infection and Immunity</i> , 1996 , 64, 3911-5	3.7	29
18	The Immunopharmacology of Immunotherapy. 1980 , 35-48		1
17	Biologic Properties of a New Synthetic Adjuvant, Muramyl Dipeptide (MDP). 1980 , 111-128		2
16	Immunopharmacologic Approaches to Bacterial Infection. 1981 , 101-107		
15	Infectious Agents in Rheumatic Diseases. 1985 , 367-395		
14	Circumvention of Neoplastic Heterogeneity by Systemically Activated Macrophages. 1986 , 311-322		
13	Muramyl Dipeptides, Host Immunity and Enhancement. 1987 , 291-300		2
12	Experimental animal models of chronic arthritis. 1988 , 157-173		1
11	Host Resistance against Bacterial Infections. 1988 , 85-107		2
10	Role of Macrophages in Recognition and Destruction of Metastatic Cells. 1989 , 144-155		
9	In Vitro Evaluation of Macrophage Mediated Host Defenses against Neoplastic Disease. 1991 , 331-341		

8	Systemic activation of macrophages by liposomes containing synthetic immunomodulators for treatment of metastatic disease. 1998 , 47-60		
7	Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1257, 133-139	3.6	6
6	Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites. <i>Immunology</i> , 1984 , 51, 517-27	7.8	25
5	Targeting the innate immune system with nanoparticles for cancer immunotherapy.. <i>Journal of Materials Chemistry B</i> , 2022 ,	7.3	2
4	Regulation of Immune Homeostasis via Muramyl Peptides-Low Molecular Weight Bioregulators of Bacterial Origin. 2022 , 10, 1526		1
3	Novel Scaffolds for Modulation of NOD2 Identified by Pharmacophore-Based Virtual Screening. 2022 , 12, 1054		1
2	Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency. 12,		0
1	Highlights into historical and current immune interventions for cancer. 2023 , 117, 109882		0